Computer-aided detection (CAD) and radiation therapy firm iCAD plans to highlight its ProFound AI platform for artificial intelligence (AI) at the upcoming French national radiology congress (JFR) in Paris.
ProFound AI comes in a digital breast tomosynthesis (DBT) version, which received the CE Mark in March 2018. In addition, ProFound AI for DBT was cleared by the U.S. Food and Drug Administration (FDA) in December 2018, iCAD said.
The company also offers ProFound AI for 2D mammography, which received the CE Mark in July 2019.
